20/20 BioLabs reported a 47.1% year-over-year increase in OneTest cancer-screening revenue to approximately $700,000 during Q2 2026 as state-funded firefighter screening programs and broader multi-cancer early detection testing drove higher laboratory volume.
OneTest accounted for more than 95% of total quarterly revenue, while consolidated revenue increased approximately 36.5% to $700,000 from $500,000. The shift increasingly concentrates the company’s business around its multi-cancer early detection platform.
The increased testing volume also produced operating leverage in the laboratory. Gross profit rose approximately 87% to $300,000, while gross margin expanded to 41.7% from 30.5% as additional tests helped absorb fixed laboratory costs.
Firefighter cancer screening is becoming an important commercial channel. Vermont launched a statewide initiative capable of screening as many as 4,500 firefighters, while Maryland fire departments received approximately $520,000 of funding for testing. 20/20 BioLabs expects its state-funded firefighter programs to contribute more than $1 million of revenue through the end of 2026.
Management expects the programs in Maryland and Vermont to help push cumulative firefighter testing above 35,000 people by year-end. Beyond direct revenue, the testing programs are generating real-world clinical data that the company believes can support future adoption and reimbursement efforts.
20/20 BioLabs also added 29 new commercial accounts and continued advancing additional channels, including an intelligence-community arrangement through the TF-7294 Foundation and a first order associated with BodyMetRX.
The company remains loss-making as it invests in commercialization. Q2 net loss was approximately $1.5 million, compared with $800,000 a year earlier, while operating expenses rose to $1.5 million from $1 million. The quarter included approximately $700,000 of non-cash expenses.
Liquidity improved materially following financing activity. Cash increased to approximately $4.5 million from $1 million at year-end, and the company eliminated convertible-note debt from its balance sheet after raising Series E preferred capital.
KEY QUOTES:
“The second quarter was the strongest quarter of multi-cancer early detection testing this Company has ever delivered. OneTest™ revenue grew 47% year-over-year to $0.7 million and represented more than 95% of total revenue, which is exactly the mix shift we have been working toward. Just as importantly, that growth came with operating leverage: gross profit increased 87% and gross margin expanded more than 11 percentage points to 41.7%, because our laboratory absorbs incremental testing volume at attractive incremental economics.”
“State-funded firefighter cancer screening continues to validate OneTest™ in a meaningful commercial setting. Programs in Maryland and Vermont are expected to help us surpass 35,000 firefighters tested by year-end, generating valuable real-world evidence while contributing to revenue growth.”
Jonathan Cohen, Chief Executive Officer of 20/20 BioLabs
